Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to Editors

Platelets to surrogate lung inflammation in COVID-19 patients

ARTICLE INFO

Keywords:
COVID-19 Platelets Pathogenesis Lung inflammation Thrombocytopenia

ABSTRACT

The neoteric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been jeopardizing the world with the symptoms of seasonal flu. The virus contagion predicted to have been originated from Wuhan, China has by far trapped 4,198,418 cases from 212 countries in the world with two international conveyances with 284,102 deaths as of 11 May 2020 (10:18 GMT). Researchers around the globe have indulged in deciphering viral mode in the body for devising a cure. Affirmations from autopsies and preliminary findings on SARS-CoV-2 hypothesized on viral pathogenesis within the host, for instance, source of inflammation in lungs and pneumonia. This hypothesis assigns the platelets as agents of infection after viral entry. Presently, curbing infection to stall the spread of SARS-CoV-2 is the prima facie intervention employed, worldwide. However, public health authorities must monitor the state of affairs scrupulously, as the deeper our understanding of this novel virus and its associated outbreak, the better we can deal with it. Knowing this idea might be far-fetched, yet this postulate would serve as the groundwork for the present situation.

Introduction

Present pandemic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the third zoonotic infectious disease crossing species barrier in the past 18 years [1]. It is a positive-sense RNA virus with ~140 nm diameter envelope, spikes around like a crown under a microscope. Bats are predicted as a powerhouse of SARS-CoV-2, and repetitive spillovers urge zoonotic diseases in mere future [2]. As of 11 May 2020, 3.4% of 4,198,418 cases have died worldwide in comparison to the seasonal-flu that effectuated the death of < 1% [3]. Infection escalates via droplets, touching contaminants followed by touching eyes, nose and mouth with no link to age and gender. The virus may be transmitted via the faecal-oral mode as it is seen in faeces and aerosolized transmission by contaminated waterworks [3] within incubation of two days-two weeks (5-d-median). The virus invades mucosal layer angiotensin-converting enzyme 2 (ACE2) cells in lungs with basic case reproduction rate (BCR) of 2 to 6.47 [4]. Amongst the registered cases 10–15% show severe pneumonia, multiple organ failure (MOF) and acute respiratory distress (ARDS) as a precursor of intravascular coagulopathy [5]. The disease’s severity highlights the need for biomarkers in the affected individuals. Some studies listed platelet counting as economic, ubiquitous and ephemeral in discriminating the coronavirus disease (COVID) into severe/moderate as thrombocytopenia is linked to COVID-19 [6].

Platelets possess Fc receptors for immunocomplexes, and surface receptors for pathogens [7]. Involvement of these receptors on platelets by immune complexes initiates intracellular signalling events that result in to platelet stimulation and aggregation. Interestingly, these events manifest in vivo, significantly in response to pathological immune complexes, and association of these receptors on platelets has been coupled to disease pathology. These receptors benefit the host by boosting immunity and protecting pathogens from leukocytes, antiviral-agent traps. The adhesiveness of platelets weakens endothelial-microbe association and enables the infection to migrate [8]. Severe acute respiratory syndrome (SARS) infection, and assisted ventilation disrupts lung-endothelium, aiding platelet activation. Lungs produce ~50% of total platelets [9], allowing virion to directly infect and produce inflammation resulting in hyaline and thick alveolar wall formation [8]. Hence, observing the interaction of SARS-CoV-2 with platelets before-and-after entry is crucial. We have postulated virion propagation and causes of pneumonia in COVID-19.

Infection’s prime site

Conventional studies revealed enhancement in platelets with a concomitant decrease in megakaryocytes (MKs) within the blood, leaving the lungs. Platelets and MKs are fully packed with growth factors and cytokines responsible for inflammation (Fig. 1). Mouse studies showed that > 10 million platelets were produced every hour from lungs that posed as the primary site for platelet biogenesis [9] with an accumulation of the required components of immune responses for instances spliceosomes, immune receptors and RNA’s from MKs [10]. The presence of pattern recognition and cytokine receptors on MKs may influence thrombopoiesis, thereby contributing to the plausible symptoms of infection, for instance, thrombocytopenia [11]. Therefore, we hypothesize that due to their omnipresence and opulence platelets enact as the primary source of cytokine storm during infection.

SARS-CoV-2-platelet communion

These tiny-cells exhibited the presence of ample surface receptors to bind or permit entry of viruses, especially the toll-like receptor family (TLRs). Studies showed an interaction between angiotensin II and TLR 4 caused pro-inflammation by kinases and transcription factors [12]. Evidence showed platelet TLR 4 receptor contributed to functional impairment and platelets stacking in the lung and liver. Possibly, SARS-CoV-2 entry from ACE-2 can release intracellular angiotensin II [13], triggering platelet degranulation. This, in turn, led to inflammation and...
loss of platelets via deposition in peripheral microvascular beds, thereby heralding symptom-thrombocytopenia and intravascular coagulopathy in COVID-19. Platelets also express human aminopeptidase-N(CD13) metalloprotease receptor of HCoV-229E. It is predicted that SARS-CoV-2 might be similar to HCoV-229E owing to 82% homology [14]. Plausibly the virion interacted with CD13 of platelets, degranulate and released inflammatory cytokines.

Platelets extravascular activity

Like Influenza-virus, it is possible the platelets could link to immunocomplexes and get activated by local agonists resulting in the inflammatory response. Vaccination showed increased inflammatory CD14, high CD16+ and thrombo-inflammation in activated platelets by FcγRIIA-immune-complexes' association. Platelets also stock mRNAs, enabling their feasibility to translate SARS-CoV-2 RNA and shield it from guardian cells [15].

Conclusion

Considering the onset of COVID-19, many researchers traced its pathogenesis. Although many unanswered questions strangle around disease mechanisms, the virus is presumed to attack endothelial cells of lung capillaries, causing a rise in plasma of the alveolar cavity. To retort SARS-CoV-2, cells like erratic platelets might release assorted pro-inflammatory cytokines, enabling recruitment of neutrophils and monocytes to clear viral residues ensuring inflammation. Platelets reveal the dual role of either suppressing or supporting certain viruses. Thrombocytopenia, ubiquitously present during viral infections, raises a major question ‘whether thrombocytopenia is a mechanism to protect the host or the virus? After multiple cross-checks on platelet's role in viral infections due to COVID-19, we hypothesized that platelets might worsen SARS-CoV-2 infections and cause pneumonia or fatality. Employing drugs like monomeric IV 3 mAb and antagonist IAXO-102 revealed inactivation of platelets and elucidated the mechanism of lung inflammation in COVID-19. However, enhanced knowledge on platelets and its immunoregulatory role during SARS-CoV-2 may go a long way in providing insights on the pandemic and aid in designing therapeutic approaches. Still, umpteen experimental trials are required to assess direct interaction of virus-platelets or the message sent by damaged endothelial cells that led to inflammation.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank ICGEB authorities especially to the Director ICGEB, New Delhi for providing the necessary infrastructure and ICGEB core funds for this research work i.e., to analyze and screen the variants for COVID19 disease. We also thank Director-General, ICGEB Trieste, Italy and Department of Biotechnology (DBT) for supporting the research activities at ICGEB. We also thank Dr. K. Sasikala, Rtd. Professor and Emeritus, School of Life Science, Bharathiar University, Coimbatore – 641046, India, and Dr. Suresh Easwaran, ENT Surgeon, Government Head Quarters Hospital, Kanchipuram, Tamil Nadu, India, for their valuable suggestions and discussions to write the manuscript.

Author contributions

HKB, ME and TK have done the literature search and drafted the paper. AM, BB, and MS helped with the literature search and revised the manuscript. SC, MS put forward the hypothesis and revised the manuscript. VA, PM, HKB, ME, AM and BB provided ideas about the mechanism of platelet receptor interaction and revised the paper. All authors approved the final version of the hypothesis.
Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.110098.

References:

[1] Perlman S. Another decade, another coronavirus. N Engl J Med 2020;382(8):760–2. https://doi.org/10.1056/NEJMe2001126.

[2] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.

[3] WHO. Coronavirus disease 2019 (COVID-19) situation report – 92. April 22, 2020. https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-92-covid-19.pdf?sfvrsn=e2bfc9c0_2 [accessed 22.04.2020].

[4] Cheng ZJ, Shan J. 2019 novel coronavirus: where we are and what we know. Infection 2020;48(2):155–63.

[5] Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med 2020;8(3):48.

[6] Lippi G, Plebani M, Michael HB. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–8.

[7] Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol 2014;5:649.

[8] Gay JJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123–34.

[9] Lefrançois E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017;544:105–9.

[10] Zufferey A, Speck ER, Machlus KR, et al. Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets. Blood Adv 2017;1:1773–85.

[11] Beaulieu LM, Lin E, Mick E, et al. Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 2014;34:552–64.

[12] Chaipan C, Soilleux EJ, Simpson P, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 2006;80:8951–60.

[13] Biancardi VC, Bomfin GF, Reis WI, Al-Gassimi S, Nunes KP. The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol Res 2017;120:88–96.

[14] Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol 2020;1–4.

[15] Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014;123:2605–13.

Haripriya Kuchi Bhotla, Tanushri Kaul, Balamuralikrishnan Balasubramanian, Muruges Easwaran, Vijaya Anand Arumugam, Manikantan Pappusamy, Saravanan Muthupandian, Arun Meyyazhagan

a Bioknowl Insights Private Limited, Coimbatore, Tamil Nadu 641046, India
b Department of Food Science and Biotechnology, College of Life Science, Sejong University, Seoul 05006, Republic of Korea
c Nutritional Improvement of Crops, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India
d Medical Genetics and Epigenetics Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tamil Nadu, India
e Department of Life Sciences, CHRIST (Deemed to be University), Bengaluru 560029 (Karnataka), India
f Department of Medical Microbiology and Immunology, Division of Biomedical Sciences, School of Medicine, College of Health Sciences, Mekelle University, Mekelle 1871, Ethiopia
g Euroespes Biomedical Research Centre, International Centre of Neuroscience and Genomic Medicine, 15165 Corunna, Spain

E-mail addresses: tanushri@icgeb.res.in (T. Kaul), arun.meyyazhagan@res.christuniversity.in (A. Meyyazhagan).